March 27, 2020 Acad, Gov/Utilities Liq. Handling & Robotics PR/Corporate

Luminex Receives FDA Emergency Use Authorization for NxTAG® CoV Extended Panel to Detect the SARS-CoV-2 Virus that Causes COVID-19 Disease

AUSTIN, Texas, March 27, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its NxTAG® CoV Extended Panel. The intended use of this multiplex test is the detection of the SARS-CoV-2 virus. High complexity molecular laboratories can now use the NxTAG test... Read more

March 13, 2020 Liq. Handling & Robotics

Luminex Provides Update on SARS-CoV-2 Validation Testing Efforts

AUSTIN, Texas, March 13, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) announced today that four independent clinical laboratories have validated laboratory developed tests (LDTs) for automated, rapid detection of the SARS-CoV-2 virus using the sample-to-answer ARIES® System. These LDTs demonstrate that high complexity laboratories using the ARIES® System can immediately add novel coronavirus diagnostics to their... Read more

March 4, 2020 Liq. Handling & Robotics

Luminex Provides Updates on Critical Efforts Related to Novel Coronavirus

AUSTIN, Texas, March 4, 2020 /PRNewswire/ — As the rapidly changing situation associated with the Wuhan coronavirus, now known as SARS-CoV-2, continues to evolve both in the United States and around the world, Luminex Corporation (NASDAQ:LMNX) announced today updates on the company’s plans, progress, and capabilities in assisting laboratories to detect and diagnose cases of this... Read more

February 24, 2020 Acad, Gov/Utilities Lab Top-10 Liq. Handling & Robotics PAI Top-10

Luminex Corporation Submits VERIGENE® II Respiratory Flex Assay for FDA Clearance

AUSTIN, Texas, Feb. 24, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that the company has submitted an application to the U.S. Food and Drug Administration (FDA) for 510(k) clearance of the VERIGENE® II Respiratory Flex Assay, the second VERIGENE II assay to be submitted to the agency. The VERIGENE® II Respiratory Flex (RSP Flex) Assay... Read more

February 18, 2020 PR/Corporate

Luminex Corporation Declares First Quarter Cash Dividend

AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ — Luminex Corporation (Nasdaq:LMNX) (the “Company”) today announced that its board of directors declared a cash dividend for the first quarter of 2020 of $0.09 per share of common stock payable on April 9, 2020 to stockholders of record as of the close of business March 19, 2020. About Luminex CorporationAt... Read more

February 13, 2020 Atomic Spectroscopy Licensing, IP, and Legal

Luminex Corporation to Participate At Upcoming Healthcare Investor Conferences in March 2020

AUSTIN, Texas, Feb. 13, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, President & CEO, and Harriss Currie, Senior Vice President of Finance and CFO, plan to participate at three investor conferences in March 2020. Morgan Stanley European MedTech & Services Conference in London, England on March 3, 2020: one-on-one investor meetings.... Read more

February 10, 2020 PAI Top-10 PR/Corporate

Luminex Corporation Reports Fourth Quarter and Full-Year 2019 Results

New Products and Effective Execution Support Return To Accelerated Organic Growth AUSTIN, Texas, Feb. 10, 2020 /PRNewswire/ — Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2019. All amounts in this release are in conformity with U.S. generally accepted accounting principles (“GAAP”). CURRENT HIGHLIGHTS Total revenue for the... Read more

January 12, 2020 Uncategorized

Luminex Corporation Announces 2019 Highlights and 2020 Guidance; Company to Present at 38th Annual J.P. Morgan Healthcare Conference

AUSTIN, Texas, Jan. 12, 2020 /PRNewswire/ — Luminex Corporation (Nasdaq: LMNX) today announced 2019 highlights and 2020 guidance. All amounts in this release are in conformity with U.S. generally accepted accounting principles (“GAAP”).   Preliminary results, contained herein, are based on management’s initial analysis of operations for the quarter and year ended December 31, 2019... Read more

December 6, 2019 PR/Corporate

Luminex Corporation Declares Fourth Quarter Cash Dividend

AUSTIN, Texas , Dec. 6, 2019 /PRNewswire/ — Luminex Corporation (Nasdaq:LMNX) (the “Company”) today announced that its board of directors declared a cash dividend for the fourth quarter of 2019 of $0.09 per share of common stock payable on January 15 , 2019 to stockholders of record as of the https://investor.luminexcorp.com/news-releases/news-release-details/luminex-corporation-declares-fourth-quarter-cash-dividend-2 Read more